Physician profile
Daniel J Kitei
NPI 1558560946
$11,463.30
in general payments reported to CMS, 2019-2025
61 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,342 · 2020: $1,742 · 2021: $1,360 · 2022: $1,300 · 2023: $1,755 · 2024: $1,489 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,717 · Education: $1.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,717.25 |
| Education | $1.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,981.06 | 2021-2025 | |
| Genzyme Corporation | $677.12 | 2019-2023 | |
| Lundbeck LLC | $640.19 | 2020-2025 | Vyepti, Rexulti |
| Ucb, INC. | $637.19 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Amgen INC. | $569.15 | 2019-2023 | Aimovig |
| Lilly USA, LLC | $526.34 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| Teva Pharmaceuticals USA, INC. | $501.45 | 2019-2021 | |
| Argenx US, INC. | $470.96 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurocrine Biosciences, INC. | $462.03 | 2020-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $362.63 | 2019-2023 | |
| Sk Life Science, INC. | $349.23 | 2020-2024 | Xcopri |
| Allergan, INC. | $316.89 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $297.88 | 2019-2024 | Ultomiris |
| Neurelis, INC. | $281.92 | 2020-2025 | Valtoco |
| Pfizer INC. | $223.98 | 2023-2025 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kitei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.